Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals

Hepatology

Volumn 66, Issue 1, 2017, Pages 27-36

  Belperio, Pamela S ^a   Shahoumian, Troy A ^a   Mole, Larry A ^a   Backus, Lisa I ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; DASABUVIR; ELBASVIR; ENTECAVIR; GRAZOPREVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TENOFOVIR; VELPATASVIR; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ELECTRONIC MEDICAL RECORD; FEMALE; FOOD AND DRUG ADMINISTRATION; HEPATITIS B; HEPATITIS C; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; VETERAN; VIRAL LOAD TESTING; VIRUS REACTIVATION; COHORT ANALYSIS; COINFECTION; DRUG EFFECTS; EVALUATION STUDY; FOLLOW UP; HEPACIVIRUS; HEPATITIS B VIRUS; IMMUNOLOGY; INCIDENCE; ISOLATION AND PURIFICATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; RISK ASSESSMENT; VIROLOGY; VIRUS ACTIVATION;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; COINFECTION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; VETERANS; VIRUS ACTIVATION;

EID: 85019264254     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29135     Document Type: Article

References (20)

1. Takayama H, Sato T, Ikeda F, Fujiki S. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res 2016;46:489-491.
2. Ende AR, Kim NH, Yeh MM, Harper J, Landis CS. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep 2015;9:164.
3. Collins JM, Raphael KL, Terry C, Cartwright EJ, Pillai A, Anania FA, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis 2015;61:1302-1306.
4. De Monte A, Courjon J, Anty R, Cua E, Nagvi A, Mondain V, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol 2016;78:27-30.
5. Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol 2017;15:132-136.
6. Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Nishimura D, et al. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis? Clin J Gastroenterol 2016;9:252-256.
7. Bersoff-Matcha SJ, Cao K, Jason M, Ajao A, Jones SC, Meyer T, et al. Hepatitis B reactivation associated with direct acting antiviral therapy for hepatitis C: a review of spontaneous post-marketing cases [Abstract]. In: Program and Abstracts of the 2016 Annual Meeting of the American Association for the Study of Liver Diseases; November 11–15, 2016; Boston, MA. Abstract LB-17.
8. Wiegand SB, Jaroszewicz J, Potthoff A, Honer Zu Siederdissen C, Maasoumy B, Deterding K, et al. Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferongamma-induced protein 10 levels in HBV/HCV-coinfected patients. Clin Microbiol Infect 2015;21:710.e1–e9.
9. Balogapal A, Thio C. Another call to cure hepatitis B. Clin Infect Dis 2015;61:1307-1309.
10. US Food and Drug Administration. FDA drug safety communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. http://www.fda.gov/Drugs/DrugSafety/ucm522932.htm. Published October 4, 2016. Accessed December 16, 2016.
11. Law MF, Ho R, Cheung CK, Tam LH, Ma K, So KC, et al. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World J Gastroenterol 2016;22:6484-6500.
12. Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015;61:703-711.
13. American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. http://hcvguidelines.org/full-report/monitoring-patients-who-are-starting-hepatitis-c-treatment-are-treatment-or-have. Accessed December 16, 2016.
14. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63:261-283.
15. Tyson GL, Kramer JR, Duan Z, Davila JA, Richardson PA, El-Serag HB. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus–infected patients. Hepatology 2013;58:538-545.
16. Ozaras R, Mete B, Tabak F. Occult hepatitis B and risk of reactivation after hepatitis C treatment with direct-acting antivirals. Clin Gastroenterol Hepatol 2016; doi:10.1016/j.cgh.2016.12.016.
17. Gane EJ, Hyland RH, An D, Svarovskaia ES, Brainard D, McHutchison JG. Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV. Antiviral Ther 2016;21:605-609.
18. Sulkowski MS, Chuang WL, Kao JH, Yang JC, Gao B, Brainard DM, et al. No evidence of reactivation of hepatitis B virus among patients treated with ledipasvir-sofosbuvir for hepatitis C virus infection. Clin Infect Dis 2016;63:1202-1204.
19. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519-528.
20. European Association for the Study of the Liver. EASL Recommendations on treatment of hepatitis C 2016. J Hepatol 2017;66:153-194.